Literature DB >> 1588974

A transcriptionally active DNA-binding site for human p53 protein complexes.

W D Funk1, D T Pak, R H Karas, W E Wright, J W Shay.   

Abstract

Recent studies have demonstrated transcriptional activation domains within the tumor suppressor protein p53, while others have described specific DNA-binding sites for p53, implying that the protein may act as a transcriptional regulatory factor. We have used a reiterative selection procedure (CASTing: cyclic amplification and selection of targets) to identify new specific binding sites for p53, using nuclear extracts from normal human fibroblasts as the source of p53 protein. The preferred consensus is the palindrome GGACATGCCCGGGCATGTCC. In vitro-translated p53 binds to this sequence only when mixed with nuclear extracts, suggesting that p53 may bind DNA after posttranslational modification or as a complex with other protein partners. When placed upstream of a reporter construct, this sequence promotes p53-dependent transcription in transient transfection assays.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588974      PMCID: PMC364481          DOI: 10.1128/mcb.12.6.2866-2871.1992

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  40 in total

1.  Formation of stable p53 homotetramers and multiples of tetramers.

Authors:  J E Stenger; G A Mayr; K Mann; P Tegtmeyer
Journal:  Mol Carcinog       Date:  1992       Impact factor: 4.784

2.  A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5'-TGACC-3' motifs acting synergistically.

Authors:  S Kato; L Tora; J Yamauchi; S Masushige; M Bellard; P Chambon
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

3.  The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein.

Authors:  T Chittenden; D M Livingston; W G Kaelin
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

4.  Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection.

Authors:  T K Blackwell; H Weintraub
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

5.  A role for both RB and p53 in the regulation of human cellular senescence.

Authors:  J W Shay; O M Pereira-Smith; W E Wright
Journal:  Exp Cell Res       Date:  1991-09       Impact factor: 3.905

6.  Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.

Authors:  U Santhanam; A Ray; P B Sehgal
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 7.  Tumor suppressor genes.

Authors:  R A Weinberg
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

8.  A potential transcriptional activation element in the p53 protein.

Authors:  R W O'Rourke; C W Miller; G J Kato; K J Simon; D L Chen; C V Dang; H P Koeffler
Journal:  Oncogene       Date:  1990-12       Impact factor: 9.867

9.  Analysis of p53 mutants for transcriptional activity.

Authors:  L Raycroft; J R Schmidt; K Yoas; M M Hao; G Lozano
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

10.  Wild-type p53 can down-modulate the activity of various promoters.

Authors:  D Ginsberg; F Mechta; M Yaniv; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

View more
  242 in total

1.  An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes.

Authors:  A L Okorokov; J Milner
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.

Authors:  G K Kovvali; B Mehta; C B Epstein; S G Lutzker
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

3.  In vitro evolution of thermostable p53 variants.

Authors:  I Matsumura; A D Ellington
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

4.  Low Grade Amplification of MDM2 Gene in a Subset of Human Breast Cancers without p53 Alterations.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

5.  Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.

Authors:  S Nakamura; J A Roth; T Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.

Authors:  E Gottlieb; R Haffner; A King; G Asher; P Gruss; P Lonai; M Oren
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

7.  Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.

Authors:  E A Komarova; M V Chernov; R Franks; K Wang; G Armin; C R Zelnick; D M Chin; S S Bacus; G R Stark; A V Gudkov
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

8.  Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene.

Authors:  J Zhao; F I Schmieg; D T Simmons; G R Molloy
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.

Authors:  S K Thukral; G C Blain; K K Chang; S Fields
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.